MARKET WIREYahoo! Finance Canada • 22h ago
CareDx, Inc. (CDNA) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering CareDx Inc. (CDNA) market action, institutional positioning, and fundamental catalysts.
Why CDNA Stock slipped -1.75% Today — RQD Quant Desk Flash
$85.88 -1.75% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $85.82
CareDx Inc. (CDNA) earns a Roarable Rating of B- (Buy) with 71/100 RQD Confidence. High-quality cash engine (steady margins, -8% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
ROARABLE B- • BUY
Cap $4.59B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on CDNA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is CDNA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, CareDx Inc. (NASDAQ: CDNA) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $85.88 (-1.75% 1D, market cap $4.59B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 19/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 10/20. Across 1015 tracked Health Care issuers, CDNA ranks #70 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does CDNA compare to CON and VCYT in the Health Care sector?
▼
Within the Health Care sector (Medical Specialities), CDNA carries a Roarable B- (71/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -8.2%. By comparison, CON (Concentra Group Holdings Parent Inc.) holds a C+ grade (68/100 RQD, P/E 31.6x, ROIC 19.7%, cap $5.15B) and VCYT (Veracyte Inc.) posts a B grade (73/100 RQD, P/E 63.2x, ROIC 4.6%, cap $4.02B). Among the 5-stock peer group, CON leads on earnings multiple (31.6x) while CON leads on capital efficiency (19.7% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for CDNA?
▼
Per CDNA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001217234), CareDx Inc. generated $379.8M in revenue (+13.8% YoY), -$21.4M in net income, and $24.9M in free cash flow against $413.2M in total assets and $49.6M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $85.81 (-0.08%)🧬 Disciplined Float (+0.52% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 6.6% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 71/100 (B-) historically ranked in the Top 14% of excess returns over the next 90 days (+6.8% avg 90D alpha vs SPY • 68.4% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERBUY • B-
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw B- · Rk B
Each axis scored 0–20
12M PRICE TARGET CONE+5.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CDNA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (71/100 Composite)
🔍 WHY CDNA SCORES 71/100 (B-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+19/20 pts (27% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (23% of score)
Altman Z-Score 19.22 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution10/20 pts (-10 pt drag)
Disciplined Float (+0.52% YoY Shares) & executive Form 4 sales trim 10 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C+$64.69+9.4% Next Q
63
Q2 (-2Q)Grade B-$70.74+2% Next Q
66
Q3 (-1Q)Grade B-$72.13+19.1% Next Q
68
CurrentGrade B-$85.88+6.8% Hist 90D α
71
Trajectory: C+ (63) → B- (71)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the CDNA Bull Thesis Could Fail
Even with a 71/100 (B-) score, CDNA faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Company executives have done more routine share selling than personal cash buying lately.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Disciplined Float (+0.52% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($61.60) or 200D SMA ($34.49) invalidates the momentum regime and cuts Target Base ($90.90) toward Bear Floor ($70.42).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $CDNA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CDNA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why CDNA Stock slipped -1.75% Today — RQD Quant Desk Flash
CareDx Inc. (CDNA) slipped -1.75% to $85.88, trading at 93% of its 52-week range ($14.27 – $90.87). High-quality cash engine (steady margins, -8% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 93% of its 52-week range ($14.27 – $90.87) with RSI-14 at 67.4 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $85.88 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable B- (Buy) backed by 52% gross margin and $24.9M annual free cash flow.
Live CDNA Headlines & Catalysts
MARKET WIREYahoo Finance Singapore • 1d ago
CareDx, Inc. (CDNA) stock price, news, quote and historyYahoo Finance Singapore report covering CareDx Inc. (CDNA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStockInvest.us • 1d ago
Caredx Stock Price Forecast. Should You Buy CDNA?StockInvest.us report covering CareDx Inc. (CDNA) market action, institutional positioning, and fundamental catalysts.
CATALYSTThe Motley Fool • 1d ago
Why CareDx Stock Soared TodayThe Motley Fool report covering CareDx Inc. (CDNA) market action, institutional positioning, and fundamental catalysts.
CATALYSTGuruFocus • 1d ago
CareDx Inc (CDNA) Shares Surge 4.8% -- What GF Score of 64 Tells InvestorsGuruFocus report covering CareDx Inc. (CDNA) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
CareDx (CDNA) Stock May Be 30% Below Fair Value On Fresh $74 TargetSimply Wall St report covering CareDx Inc. (CDNA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Stock vesting triggers 997-share tax withholding for CareDx (CDNA) counsel Jeffrey Adam Novack.Stock Titan report covering CareDx Inc. (CDNA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREwww.marketscreener.com • 1d ago
Earnings Flash (CDNA) CareDx, Inc. Posts Q3 Adjusted EPS $0.70 per Sharewww.marketscreener.com report covering CareDx Inc. (CDNA) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 2d ago
CareDx (CDNA) Stock Still Looks Reasonable Following Its Huge 3 Year RunCareDx has been on a powerful multi‑year run, and the latest surge in transplant testing news has pushed the valuation conversation back to basics: its cash flows. With the stock now in a very different place to three ye
MARKET WIREChartMill • 3d ago
Gap-Up and Gap-Down Stocks for October 30, 2026October 30, 2026 gap list shows sharp opening gaps and session moves for gap-up stocks such as GDYN and gap-down stocks such as ATEC.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (CDNA Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CDNA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +309.73%▲ ASCENDING CHANNEL
2026-11-03O $71.52H $87.41L $71.52C $85.88VOL 3.56M
RES: $92.83SUP: $71.34SMA50: $61.60SMA200: $34.49
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CDNA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
14.6%/yr Implied 5Y Growth
vs. +13.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on CDNA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for CDNA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CDNA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CDNA)
Health Care Rank #70 of 1015
⚔️ CON vs CDNA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (CDNA vs. CON, VCYT, BLLN, RDNT)
Industry: Medical Specialities (41 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, CareDx Inc. (CDNA) ranks #70 by composite RQD confidence (71/100, grade B-) and #169 by equity capitalization ($4.59B). Within this direct 5-issuer industry benchmark cohort, CON leads on earnings valuation at 31.6x trailing P/E, while CON leads on capital efficiency and profitability with 19.7% ROIC and — gross margin. VCYT currently holds the highest overall quantitative score in the immediate peer group at 73/100 (B) compared with CDNA at 71/100 (B-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CDNA
ACTIVE
CareDx Inc. | B- | 71/100 | — | — | -8.2% | -1.75% | $4.59B | Benchmark Subject |
| CON Concentra Group Holdings Parent Inc. | C+ | 68/100 | 31.6x | — | 19.7% | -0.12% | $5.15B | /con-vs-cdna → |
| VCYT Veracyte Inc. | B | 73/100 | 63.2x | 70.1% | 4.6% | -2.02% | $4.02B | /vcyt-vs-cdna → |
| BLLN BillionToOne Inc. | B- | 70/100 | — | 68.3% | 2.9% | -2.57% | $5.35B | /blln-vs-cdna → |
| RDNT RadNet Inc. | D+ | 57/100 | — | — | 3.5% | -0.53% | $5.78B | /rdnt-vs-cdna → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001217234 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), CareDx Inc. (CDNA) reported GAAP revenue of $379.8M (+13.8% vs. FY2024 revenue of $333.8M , and +35.5% cumulative change since FY2023) , GAAP net income of -$21.4M, operating cash flow of $42.0M, and free cash flow of $24.9M (+8.3% YoY). On the balance sheet, CDNA closed FY2025 with $413.2M in total assets against $49.6M in total debt (Altman Z-Score: 19.22, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $379.8M | -$21.4M | $42.0M | $24.9M | $413.2M | $49.6M |
| FY2024 (FY) | 2024-12-31 | $333.8M | $52.5M | $38.0M | $23.0M | $491.1M | $50.7M |
| FY2023 (FY) | 2023-12-31 | $280.3M | -$190.3M | -$18.4M | -$31.0M | $2.04B | $476.2M |
3. CDNA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs CDNA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, CareDx Inc. (NASDAQ: CDNA) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $85.88 (-1.75% 1D, market cap $4.59B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 19/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 10/20. Across 1015 tracked Health Care issuers, CDNA ranks #70 in composite RQD confidence.
How does CDNA compare to CON and VCYT in the Health Care sector?
Within the Health Care sector (Medical Specialities), CDNA carries a Roarable B- (71/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -8.2%. By comparison, CON (Concentra Group Holdings Parent Inc.) holds a C+ grade (68/100 RQD, P/E 31.6x, ROIC 19.7%, cap $5.15B) and VCYT (Veracyte Inc.) posts a B grade (73/100 RQD, P/E 63.2x, ROIC 4.6%, cap $4.02B). Among the 5-stock peer group, CON leads on earnings multiple (31.6x) while CON leads on capital efficiency (19.7% ROIC).
What are the biggest fundamental strengths and SEC risk factors for CDNA?
Per CDNA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001217234), CareDx Inc. generated $379.8M in revenue (+13.8% YoY), -$21.4M in net income, and $24.9M in free cash flow against $413.2M in total assets and $49.6M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is CDNA trading relative to its 50-day, 200-day, and 52-week technical levels?
CDNA last traded at $85.88 (-1.75% on volume of 2,354,919 shares), positioning the stock +39.42% above its 50-day simple moving average ($61.60) and +149.00% above its 200-day simple moving average ($34.49). Across its 52-week range of $14.27 to $90.87, CDNA sits at the 93.5% percentile with a 14-day RSI of 67.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($75.15 to $96.61).
ROARABLE RATING BRIEF • RQD 71/100 (B-)
✓ SEC XBRL & RQD VERIFIED
CDNA — CareDx Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
CareDx Inc. (CDNA) earns a live Roarable RQD composite score of 71/100, corresponding to a B- letter grade (Roarable Buy) at a spot price of $85.88 (-1.75% 1D, market capitalization $4.59B).
- Fundamental Cash Engine (13/20): Anchored by return on invested capital (ROIC) of -8.2%, gross margin of —, operating margin of -8.1%, and free cash flow yield of 0.67%.
- Whale 13F & Options Flow (19/20) + Insider Conviction (10/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (13/20) + Forensic Balance Sheet (16/20): Incorporates a 1.06x equity beta, Altman Z-Score of 19.22, Piotroski F-Score of 7/9, and Debt/Equity of 0.15x.
2. Business Model, Unit Margins & SEC Financial Trajectory
CareDx Inc. Is a NASDAQ-listed issuer in the Health Care sector, Medical Specialities industry. The profile identifies the company as operating in Medical Specialities with a market capitalization of $3.7B. Revenue of $379.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), CareDx Inc. (CDNA) reported $379.8M in annual revenue (up from $333.8M in FY2024, +13.8% YoY) and -$21.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($280.3M revenue, -$190.3M net income) through FY2025, CDNA scaled operating cash flow to $42.0M and free cash flow to $24.9M, backed by $413.2M in total assets against $49.6M in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (B- • RQD 71/100): Big institutional funds and options desks are actively positioning on the bullish side. Clean SEC annual filing review with no major hidden accounting time-bombs. With Fundamental Cash Engine at 13/20 and Institutional Whale Flow at 19/20, sustained execution supports upside toward the upper end of the $14.27 – $90.87 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -8.1% operating margins and a 1.06x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the provided sources. The only sector context available is the classification as Health Care / Medical Specialities.
- Key Question #1: Can CDNA sustain or expand its -8.1% operating margin and -8.2% ROIC against Medical Specialities peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $379.8M and free cash flow of $24.9M, how will capital allocation balance growth reinvestment against $49.6M in total debt?
- Key Question #3: How sensitive is CDNA's 21.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.06x)?
CDNA Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for CareDx Inc. (CDNA) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo! Finance Canada • 22h ago
CareDx, Inc. (CDNA) Stock Price, News, Quote & History Yahoo! Finance Canada report covering CareDx Inc. (CDNA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance Singapore • 1d ago
CareDx, Inc. (CDNA) stock price, news, quote and history Yahoo Finance Singapore report covering CareDx Inc. (CDNA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE StockInvest.us • 1d ago
Caredx Stock Price Forecast. Should You Buy CDNA? StockInvest.us report covering CareDx Inc. (CDNA) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST The Motley Fool • 1d ago
Why CareDx Stock Soared Today The Motley Fool report covering CareDx Inc. (CDNA) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST GuruFocus • 1d ago
CareDx Inc (CDNA) Shares Surge 4.8% -- What GF Score of 64 Tells Investors GuruFocus report covering CareDx Inc. (CDNA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
CareDx (CDNA) Stock May Be 30% Below Fair Value On Fresh $74 Target Simply Wall St report covering CareDx Inc. (CDNA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Stock vesting triggers 997-share tax withholding for CareDx (CDNA) counsel Jeffrey Adam Novack. Stock Titan report covering CareDx Inc. (CDNA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE www.marketscreener.com • 1d ago
Earnings Flash (CDNA) CareDx, Inc. Posts Q3 Adjusted EPS $0.70 per Share www.marketscreener.com report covering CareDx Inc. (CDNA) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
CDNA Bull vs. Bear Conversation Board — What's Your Call at $85.88?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CDNA 🐻 33% BEARISH CONVICTION
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH
🎯 Target: $107.51 (+23.0%)
📌 Pinned Debate Institutional accumulation and options positioning (17/20, the strongest RQD pillar) combined with a forensic balance sheet (Altman Z 1
The street is overcomplicating CareDx Inc. (CDNA). Institutional accumulation and options positioning (17/20, the strongest RQD pillar) combined with a forensic balance sheet (Altman Z 19.22, Debt/Equity 0.15) suggest financial stability and institutional support beneath the stock.. With an RQD score of 71/100 (B-) and Forensic Balance Sheet at 16/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $94.40.
SectorRotator 🐂 BULL
@BearTrap_Alert Fair point on 21.0x forward P/E, but you're ignoring the forward operating leverage in Medical Specialities. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.
BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH
🎯 Target: $70.80 (-19.0%)
Spot @ $87.41 Negative ROIC of -8.2%, operating margin of -8.1%, and a swing from $40.8M operating income in FY 2024 to -$30.8M in FY 2025 indicate w
Careful chasing CDNA at $87.41. Negative ROIC of -8.2%, operating margin of -8.1%, and a swing from $40.8M operating income in FY 2024 to -$30.8M in FY 2025 indicate weakening profitability and a valuation resting on an earnings recovery not yet visible in trailing EPS of -0.41.. Gross margin is 0.0%, but operating margin is -8.1%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $70.80 on multiple compression.